Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice

Over the last 30 years, widespread efforts to characterize chromosomal abnormalities, genomic mutations, epigenetic alterations, and proteomic changes in cancer cells have rapidly increased our understanding of the molecular biology of neoplasia.1-6 These advances have challenged the histology-centric paradigm of tumor classification, demanding a reassessment of current diagnostic algorithms and categories and development of novel strategies for incorporating molecular and genetic data into the nosology of neoplasia.7 A new paradigm is emerging, highlighted by the publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System,8 which adopts, for the first time, diagnoses that integrate both histologic and molecular parameters. Application of these recent changes in the criteria and taxonomy of CNS tumors and in clinical practice results in both challenges and opportunities that are many and varied. HISTOLOGIC CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMORS Section: ChooseTop of pageAbstractHISTOLOGIC CLASSIFICATION... <